Understanding NeuroStar TMS Therapy for Depression and Anxiety
This study is looking back at information from many people who have already received NeuroStar Advanced TMS Therapy System (a non-invasive brain stimulation device) for conditions like depression, obsessive-compulsive disorder, and anxiety. The goal is to learn how different patient characteristics, symptoms, and treatment settings affect how well the therapy works. Researchers will look at changes in clinical assessment scores from before treatment to 8 weeks after treatment to see how much symptoms improved. You could be included if you are between 5 and 120 years old, male or female, and received treatment on or after November 1, 2008. The study is currently unclear on its recruitment status.
- Study design
- This is an observational study, meaning researchers are looking at existing information rather than conducting new treatments. It plans to include a large number of participants, up to 156,000.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome is measured at 8 weeks after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Retrospective Analyses of TrakStar Database
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Eleanor Cole, PhD · STUDY_DIRECTOR · Neuronetics
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Change in clinical assessment score from baseline to post-treatment8 weeks
real-world efficacy of NeuroStar TMS in reducing patients' symptoms, reduction in clinical assessment score like PHQ-9